Livforsakringsbolaget Skandia, Omsesidigt Harmony Biosciences Holdings, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.72 Billion
- Q3 2024
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 44,900 shares of HRMY stock, worth $1.53 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
44,900
Previous 24,300
84.77%
Holding current value
$1.53 Million
Previous $733,000
144.61%
% of portfolio
0.1%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding HRMY
# of Institutions
242Shares Held
45.1MCall Options Held
108KPut Options Held
49.2K-
Valor Management LLC Chicago, IL11.2MShares$382 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$199 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$118 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$88.8 Million15.24% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.93MShares$65.7 Million0.18% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.02B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...